Rubicon Research Limited (RUBICON)
Outcome of Board Meeting
FY2026 results:
Standalone:
Revenue 13.1bn +21% y-y (10.6bn)
EBITDA 3.1bn +32% y-y (2.3bn)
EBITDA margin 23.6% (21.1%) +250 bps y-y
PAT 1.9bn +17% y-y (1.6bn)
Consolidated:
Revenue 17.5bn +22% y-y (14.4bn)
EBITDA 3.2bn +27% y-y (2.5bn)
EBITDA margin 18.4% (17.3%) +110 bps y-y
PAT 2.5bn +17% y-y (2.1bn)
Dividend: 1.50/share (approved at AGM on August 26, 2026)
Commentary: The Board approved a Scheme of Amalgamation with Kia Health Tech Private Limited; acquisition of Arinna Lifesciences Limited completed April 30, 2026; IPO proceeds utilization extended to March 31, 2027.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 RUBICON — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add RUBICON to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Rubicon Research Limited
Important.
The summary above is generated automatically from Rubicon Research Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.